parkinson-s-disease

Documents about parkinson-s-disease

• REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study#808100ClinicalTrials.gov
• Microbiome Composition and Function Contributes to Cognitive Impairment and Neuroinflammation in Parkinson's Disease#810274ClinicalTrials.gov
• Motor Adaptation to Split-Belt Treadmill in Parkinson's Disease#811359ClinicalTrials.gov
• Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients#835230ClinicalTrials.gov
• Effects of Vitamin D in Parkinson's Disease (PD)#836964ClinicalTrials.gov
• Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Constipation in Parkinson's Disease#839976ClinicalTrials.gov
• Impact of C-Mill Rehabilitation on the Gut-Brain Axis in Parkinson's Disease#845294ClinicalTrials.gov
• Fesoterodine on Urgency Episodes in Parkinson's Disease Population#869172ClinicalTrials.gov
• Effects of Directional Subthalamic Deep Brain Stimulation on Gait and Balance in Parkinson's Disease Patients#870584ClinicalTrials.gov
• Caffeine for Motor Manifestations of Parkinson's Disease#831515ClinicalTrials.gov
• Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients#856567ClinicalTrials.gov
• Genetic landscape of Parkinson's disease in the Personalized Parkinson Project cohort#67980bioRxiv / medRxiv
• Help-seeking for Health Problems in People With Parkinson's#871975ClinicalTrials.gov
• The Effects of Scapulohumeral Rehabilitation on Scapula Kinematics and Upper Extremity Functionality in Individuals With Parkinson's Disease#858392ClinicalTrials.gov
• Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202#861451ClinicalTrials.gov
• Theiler's murine encephalomyelitis virus as the infectious agent for a virally induced mouse model of Parkinson's disease#123209Europe PMC
• Associations of Non-motor Symptoms with Perceptual Speech Impairments in Parkinson’s Disease#433027DigitalCommons@SHU
• Dopaminergic nigrostriatal vulnerability in Parkinson's Disease with diabetes: evidence from severity-matched cohorts#676462Europe PMC
• Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression#800591ClinicalTrials.gov
• Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET#800615ClinicalTrials.gov
• CuePD: Investigating the Effect of Personalised Auditory Cueing on Gait in Parkinson's Disease#805387ClinicalTrials.gov
• Effect of Transcranial Magnetic Stimulation on Cognition and Neural Changes in Parkinson's Disease#810986ClinicalTrials.gov
• Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease#836840ClinicalTrials.gov
• Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact#850742ClinicalTrials.gov
• Short Pulse Width Versus Low Frequency DBS in Parkinson's Disease#856700ClinicalTrials.gov
• Accelerated TMS for Freezing of Gait in Parkinson's Disease#874186ClinicalTrials.gov
• Digital BIOmarkers for the Assessment of Motor Status in Parkinson's Disease Patients with CLInical and ThErapeutic Application#828138ClinicalTrials.gov
• Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off#841452ClinicalTrials.gov
• A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia#827364ClinicalTrials.gov
• Telemedicine Intervention to Improve Physical Function#832289ClinicalTrials.gov
• Virtual Reality Effects on Functional Capacity and Quality of Life of People With Parkinson's Disease#837936ClinicalTrials.gov
• Retinal Biomarkers in Parkinson´s Disease#852084ClinicalTrials.gov
• Evaluation of Neurocognitive Changes in Parkinson's Disease After Low Frequency Burst Stimulation#854148ClinicalTrials.gov
• Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease#870821ClinicalTrials.gov
• Association of peripheral and CSF zinc levels with Parkinson's disease: A systematic review and meta-analysis#5269Europe PMC
• Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease#832429ClinicalTrials.gov
• Interactive Home-based Rehabilitation Exercise Assessment Platform and Exploration of Clinical Effects in Patients with Parkinson's Disease#859333ClinicalTrials.gov
• Integrated Multidisciplinary Care for Parkinson's Disease: a Controlled Trial#800400ClinicalTrials.gov
• Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients#854738ClinicalTrials.gov
• Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists#868815ClinicalTrials.gov
• Usability Study of a Neuropsychological Intervention Program Based on Virtual Reality in Adults With Parkinson's Disease#843502ClinicalTrials.gov
• Treatment of Parkinson's Disease With Eliprodil#803592ClinicalTrials.gov
• Dyskinesia in Parkinson's Disease (Study P04501)#825661ClinicalTrials.gov
• Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease#825994ClinicalTrials.gov
• Physical Therapy and Cognitive Decline#829916ClinicalTrials.gov
• Melatonin on Clock Genes in Parkinson's Disease#835915ClinicalTrials.gov
• Exercise Adherence and Optimal Nutrition Post Rehabilitation Among People With Parkinson's Disease#836042ClinicalTrials.gov
• Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease#839168ClinicalTrials.gov
• Behavioral Treatments for Anxiety and Depression in Veterans With Parkinson's Disease#842252ClinicalTrials.gov
• Combined Deep Brain Stimulation in Parkinson's Disease#867822ClinicalTrials.gov